Maryland SB608 mandates coverage for single-gene and multigene pharmacogenomic testing by insurers and health plans.

Maryland SB608 requires insurers, nonprofit health services plans, and health maintenance organizations to cover single-gene and multigene pharmacogenomic testing, which evaluates how an individual's genetic profile may impact medication efficacy, safety, or toxicity. The bill limits prior authorization requirements for such testing, ensuring timely access and minimizing administrative burdens. Non-compliant entities face monetary penalties and corrective action plans. The law takes effect on July 1, 2027.

Maryland SB608 mandates coverage for single-gene and multigene pharmacogenomic testing by insurers and health plans.

Maryland SB608 requires insurers, nonprofit health services plans, and health maintenance organizations to cover single-gene and multigene pharmacogenomic testing, which evaluates how an individual's genetic profile may impact medication efficacy, safety, or toxicity. The bill limits prior authorization requirements for such testing, ensuring timely access and minimizing administrative burdens. Non-compliant entities face monetary penalties and corrective action plans. The law takes effect on July 1, 2027.